Search Results 141-150 of 19317 for B cell lymphomas

  1. Publications - Grzegorz S. Nowakowski, M.D. - Mayo Clinic

    Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin. Cancer Epidemiol Biomarkers Prev ...

  2. Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis - Mayo Clinic

    Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell ...

  3. Arushi Khurana, M.B.B.S. - Doctors and Medical Staff - Mayo Clinic

    ... lymphomas and cellular therapy. Her clinical and research focus includes: Expertise in management of various types of lymphomas such as diffuse large B-cell ...

  4. CAR-T Cell Therapy Program - Department home - Mayo Clinic

    CAR-T cell therapy may be a treatment option for: Relapsed, refractory B-cell acute lymphoblastic leukemia; Relapsed, refractory B-cell non-Hodgkin's lymphoma ...

  5. T-cell lymphoma - Doctors and departments - Mayo Clinic

    ... b-cell lymphoma, Diffuse large b-cell lymphoma, Follicular lymphoma, B-cell lymphoma, T-cell lymphoma. Show more areas of focus for Muhamad Alhaj Moustafa ...

  6. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) - Mayo Clinic

    About this study. In this study, participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory ...

  7. Publications - Rebecca L. King, M.D. - Mayo Clinic

    ... B-Cell Lymphoma Subtype Defined by the Cell of Origin. ... Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young ...

  8. Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma - Mayo Clinic

    ... B-cell lymphomas. Clinically, four weekly doses of rituximab have proven to be well tolerated and effective in previously untreated as well as relapsed ...

  9. A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Mayo Clinic

    ... B-cell Lymphoma (DLBCL). Print details. Share; Facebook · Twitter. Overview ... RTX and BEN are both approved in many countries for the treatment of lymphomas.

  10. CAR-T Cell Therapy Program - Overview - Mayo Clinic

    Relapsed, refractory B-cell acute lymphoblastic leukemia; Relapsed, refractory B-cell non-Hodgkin's lymphoma; Relapsed, refractory mantle cell lymphoma ...